teva-lamivudine/zidovudine comprimé
teva canada limited - lamivudine; zidovudine - comprimé - 150mg; 300mg - lamivudine 150mg; zidovudine 300mg - nucleoside and nucleotide reverse transcriptase inhibitors
teva-emtricitabine/tenofovir comprimé
teva canada limited - emtricitabine; fumarate de ténofovir disoproxil - comprimé - 200mg; 300mg - emtricitabine 200mg; fumarate de ténofovir disoproxil 300mg - nucleoside and nucleotide reverse transcriptase inhibitors
auro-lamivudine/zidovudine comprimé
auro pharma inc - lamivudine; zidovudine - comprimé - 150mg; 300mg - lamivudine 150mg; zidovudine 300mg - nucleoside and nucleotide reverse transcriptase inhibitors
auro-abacavir/lamivudine comprimé
auro pharma inc - abacavir (sulfate d'abacavir); lamivudine - comprimé - 600mg; 300mg - abacavir (sulfate d'abacavir) 600mg; lamivudine 300mg - nucleoside and nucleotide reverse transcriptase inhibitors
teva-valacyclovir comprimé
teva canada limited - valaciclovir (chlorhydrate de valacyclovir) - comprimé - 1000mg - valaciclovir (chlorhydrate de valacyclovir) 1000mg - nucleosides and nucleotides
bleomycin for injection usp poudre pour solution
sandoz canada incorporated - bléomycine (sulfate de bléomycine) - poudre pour solution - 15unité - bléomycine (sulfate de bléomycine) 15unité - antineoplastic agents
zidovudine oral solution usp
aurobindo pharma limited (unit iii) - zidovudine - solution - 50mg - zidovudine 50mg - nucleoside and nucleotide reverse transcriptase inhibitors
nasensalbe rüedi spirig hc pommade
spirig healthcare ag - menthae piperitae aetheroleum, camphorae solution oleosa - pommade - menthae piperitae aetheroleum 2 mg, camphorae solution oleosa 4 mg, vaselinum album, paraffinum liquide, de la graisse avec 40 mg d'alcool et de cetylicus et stearylicus 16 mg, propylis parahydroxybenzoas 2 mg, e-218 2 mg, e 320 0,1 mg, eau q.s. le parfum pour 1 g de la. - en cas de sécheresse de la muqueuse nasale - synthetika
evotaz
bristol-myers squibb pharma eeig - cobicistat, atazanavir - infections au vih - antiviraux à usage systémique - evotaz is indicated in combination with other antiretroviral medicinal products for the treatment of hiv-1 infected adults and adolescents (aged 12 years and older weighing at least 35 kg) without known mutations associated with resistance to atazanavir (see sections 4. 4 et 5.
nulojix
bristol-myers squibb pharma eeig - belatacept - graft rejection; kidney transplantation - immunosuppresseurs - nulojix, in combination with corticosteroids and a mycophenolic acid (mpa), is indicated for prophylaxis of graft rejection in adult recipients of a renal transplant.